CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
10.56
-0.08 (-0.75%)
At close: Dec 5, 2025, 4:00 PM EST
10.60
+0.04 (0.38%)
After-hours: Dec 5, 2025, 7:58 PM EST
CorMedix Employees
As of December 31, 2024, CorMedix had 65 total employees, including 64 full-time and 1 part-time employees. The number of employees decreased by 18 or -21.69% compared to the previous year.
Employees
65
Change (1Y)
-18
Growth (1Y)
-21.69%
Revenue / Employee
$3,296,980
Profits / Employee
$2,499,989
Market Cap
832.01M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRMD News
- 21 days ago - CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating - Seeking Alpha
- 23 days ago - Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 24 days ago - CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations - Benzinga
- 24 days ago - CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance - GlobeNewsWire
- 5 weeks ago - CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 - GlobeNewsWire
- 6 weeks ago - CorMedix: Strong Buy After Strong Developments And A Strategy Before Earnings - Seeking Alpha
- 6 weeks ago - CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath - GlobeNewsWire